In 2016, an objective definition of secondary progressive MS was proposed, based on the application of a mathematical algorithm to longitudinally recorded EDSS score evaluations in the MSBase platform [3]. Caution should be taken, because the way conversion is defined may affect the risk and protective factors eventually associated with the disease course transition. So far, no studies have evaluated the risk factors for conversion using different secondary progressive MS definitions.
In a large cohort of relapsing-remitting MS patients (n=19,318) extracted from the Italian MS Registry, two different definitions of secondary progressive MS were applied:
- Firstly, the date of conversion annotated in the database, which was based on the subjective judgement of the neurologists, was extracted;
- Secondly, a data-driven definition based on an EDSS increase, in the absence of a relapse, with a minimum EDSS ≥4 and pyramidal score ≥2 at time of conversion [4].
The risk of reaching the secondary progressive MS was assessed by using multivariate Cox proportional hazards models. A data-driven definition of secondary progressive MS seems to select a population more likely to be in the progressive phase of the disease in comparison to the diagnosis of the neurologist.
By using both the definitions, Dr Pietro Iaffaldano (University of Bari Aldo Moro, Italy) and colleagues confirmed that the most important risk factors for the transition of relapsing-remitting MS to secondary progressive MS are a multifocal onset, an older age of onset, and a higher number of relapses. Furthermore, they confirmed that the most important protective factor against the transition to secondary progressive MS is disease-modifying treatment exposure. “The higher the exposure, the lower the risk of progression”, he added.
After transition, disease-modifying treatment exposure does not have an impact on the risk of disability accrual. The major driver of disability accumulation in this phase of the disease are relapses. So, an accurate and less ambiguous secondary progressive MS definition is warranted to assist the neurologists and the scientific community in the efforts to find newer treatment strategies against progressive MS [4].
- Lublin FD, Reingold SC. Neurology. 1996;46:907-11.
- Lublin FD, et al. Neurology. 2014;83:278-86.
- Lorscheider J, et al. Brain. 2016;139(Pt 9):2395-405.
- Iaffaldano P, et al. ECTRIMS 2019, abstract 156.
Posted on
Previous Article
« Genes, environment, and safety monitoring in using registries Next Article
Foetal/child perspective: risks related to drug exposure and breastfeeding »
« Genes, environment, and safety monitoring in using registries Next Article
Foetal/child perspective: risks related to drug exposure and breastfeeding »
Table of Contents: ECTRIMS 2019
Featured articles
Towards a Comprehensive Assessment of MS Course
Cognitive assessment in MS
Late-breaking: Role for CSF markers in autoimmune astrocytopathies
Targeted therapies for NMOSD in development
Monitoring and Treatment of Progressive MS
Challenges in diagnosing and treating progressive MS
Risk factors for conversion to secondary progressive MS
Transplantation of autologous mesenchymal stem cells
Sustained reduction in disability progression with ocrelizumab
Late-breaking: Myelin-peptide coupled red blood cells
Optimising Long-Term Benefit of MS Treatment
Induction therapy over treatment escalation
Treatment escalation over induction therapy
Influence of age on disease progression
Exposure to DMTs reduces disability progression
Predicting long-term sustained disability progression
Treatment response scoring systems to assess long term prognosis
Safety Assessment in the Post-Approval Phase
Use of clinical registries in phase 4 of DMT
Genes, environment, and safety monitoring in using registries
Risk of hypogammaglobulinemia and rituximab
Determinants of outcomes for natalizumab-associated PML
Serum immunoglobulin levels and risk of serious infections
EAN guideline on palliative care
Pregnancy in the Treatment Era
The maternal perspective: when to stop/resume treatment and risks for progression
Foetal/child perspective: risks related to drug exposure and breastfeeding
Patient awareness about family planning represents a major knowledge gap
Late-breaking: Continuation of natalizumab or interruption during pregnancy
Related Articles
November 18, 2024
Encouraging real-world results of AHSCT to treat aggressive MS
April 29, 2021
Does fampridine improve upper limb function in MS?
December 9, 2021
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com